Floatz logo

Enasidenib

Recurrent Acute Myeloid Leukemia

Children's Oncology GroupSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

684 Active assets in the Recurrent Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
Posaconazole
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

Enasidenib is also rated in:

Isocitrate DehydrogenaseDormant
BB
Indicative ·
64 / 100
View asset →
IDH2 Gene MutationDormant
BB
Indicative ·
64 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →